Watchlist Price Alert

Novo Nordisk A/S (NVO)

NYSE: NVO · Real-Time Price · USD

76.87

-2.96 (-3.71%)

At close: Jun 16, 2025, 2:24 PM

-3.71% (1D)

Bid	76.86
Market Cap	343.43B
Revenue (ttm)	303.14B
Net Income (ttm)	104.61B
EPS (ttm)	3.62
PE Ratio (ttm)	21.23
Forward PE	2.38
Analyst	Buy

Ask	76.87
Volume	5,960,436
Avg. Volume (20D)	10,020,517
Open	77.84
Previous Close	79.83
Day's Range	76.79 - 78.38
52-Week Range	57.00 - 148.15
Beta	0.22

About NVO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NVO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 days ago

+2.95%

Novo Nordisk shares are trading higher after the c... Unlock content with Pro Subscription

6 days ago

+5.13%

Novo Nordisk shares are trading higher. The company announced it will present data from the STEP UP trial on the higher dose if Wegovy at the American Diabetes Association 85th Scientific Sessions.

News

6 hours ago · zacks.com

Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

1 hour ago · fool.com

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk.

4 hours ago · seekingalpha.com

Novo Nordisk: The Strength To Withstand Challenges

Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could co...

4 hours ago · marketwatch.com

The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars

Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

2 days ago · barrons.com

Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out.

The Danish drug maker is being more forceful since its CEO departed last month.

2 days ago · youtube.com

The Big 3: NVO, DIS, WHR

Andrew Arons joins today's Big 3 to talk about stocks he believes can make 20% moves over the next year. He sees Novo Nordisk (NVO) benefitting off a rising weight-loss drug trends, Walt Disney (DIS) ...

2 days ago · zacks.com

NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.

3 days ago · reuters.com

Novo Nordisk regains crown as Europe's most valuable company

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP on Friday.

3 days ago · marketwatch.com

After ousting CEO, Novo Nordisk reclaims crown as largest European company

Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization.

4 days ago · zacks.com

Why Novo Nordisk (NVO) Outpaced the Stock Market Today

Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.

Load More News